Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6,302 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical Impact of Antibodies against Ustekinumab in Psoriasis: An Observational, Cross-Sectional, Multicenter Study.
Loeff FC, Tsakok T, Dijk L, Hart MH, Duckworth M, Baudry D, Russell A, Dand N, van Leeuwen A, Griffiths CEM, Reynolds NJ, Barker J, Burden AD, Warren RB, de Vries A, Bloem K, Wolbink GJ, Smith CH, Rispens T; BADBIR; BSTOP Study Groups; PSORT consortium. Loeff FC, et al. J Invest Dermatol. 2020 Nov;140(11):2129-2137. doi: 10.1016/j.jid.2020.03.957. Epub 2020 Apr 10. J Invest Dermatol. 2020. PMID: 32283057 Free article.
Intentional and Unintentional Medication Non-Adherence in Psoriasis: The Role of Patients' Medication Beliefs and Habit Strength.
Thorneloe RJ, Griffiths CEM, Emsley R, Ashcroft DM, Cordingley L; British Association of Dermatologists Biologic Interventions Register; Psoriasis Stratification to Optimise Relevant Therapy Study Groups. Thorneloe RJ, et al. J Invest Dermatol. 2018 Apr;138(4):785-794. doi: 10.1016/j.jid.2017.11.015. Epub 2017 Nov 26. J Invest Dermatol. 2018. PMID: 29183731 Free PMC article.
Risks of basal cell and squamous cell carcinoma in psoriasis patients after treatment with biologic vs non-biologic systemic therapies.
Mason KJ, Burden AD, Barker JNWN, Lunt M, Ali H, Kleyn CE, McElhone K, Soliman MM, Green AC, Griffiths CEM, Reynolds NJ, Ormerod AD; BADBIR Study Group. Mason KJ, et al. J Eur Acad Dermatol Venereol. 2021 Aug;35(8):e496-e498. doi: 10.1111/jdv.17282. Epub 2021 May 3. J Eur Acad Dermatol Venereol. 2021. PMID: 33866626 No abstract available.
Using Real-World Data to Guide Ustekinumab Dosing Strategies for Psoriasis: A Prospective Pharmacokinetic-Pharmacodynamic Study.
Pan S, Tsakok T, Dand N, Lonsdale DO, Loeff FC, Bloem K, de Vries A, Baudry D, Duckworth M, Mahil S, Pushpa-Rajah A, Russell A, Alsharqi A, Becher G, Murphy R, Wahie S, Wright A, Griffiths CEM, Reynolds NJ, Barker J, Warren RB, David Burden A, Rispens T, Standing JF, Smith CH; BADBIR Study Group, the BSTOP Study Group, the PSORT Consortium. Pan S, et al. Clin Transl Sci. 2020 Mar;13(2):400-409. doi: 10.1111/cts.12725. Epub 2020 Jan 29. Clin Transl Sci. 2020. PMID: 31995663 Free PMC article.
A summary of the updated report on the incidence and epidemiological trends of keratinocyte cancers in the UK 2013-2018.
Kwiatkowska M, Ahmed S, Ardern-Jones MR, Bhatti LA, Bleiker TO, Gavin A, Hussain S, Huws DW, Irvine L, Langan SM, Millington GWM, Mitchell H, Murphy R, Paley L, Proby CM, Thomson CS, Thomas R, Turner C, Vernon S, Venables ZC. Kwiatkowska M, et al. Among authors: hussain s. Br J Dermatol. 2022 Feb;186(2):367-369. doi: 10.1111/bjd.20764. Epub 2021 Nov 24. Br J Dermatol. 2022. PMID: 34564854 No abstract available.
6,302 results